Winslow Evans & Crocker’s Sarepta Therapeutics SRPT Stock Holding History

Winslow Evans & Crocker’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$13K	Hold	75	–	–	﹤0.01%	900
2020 Q3	$11K	Hold	75	–	–	﹤0.01%	736
2020 Q2	$12K	Sell	75 -1	-1%	-$136	﹤0.01%	708
2020 Q1	$8K	Hold	76	–	–	﹤0.01%	768
2019 Q4	$10K	Hold	76	–	–	﹤0.01%	831
2019 Q3	$6K	Hold	76	–	–	﹤0.01%	939
2019 Q2	$12K	Hold	76	–	–	﹤0.01%	788
2019 Q1	$10K	Hold	76	–	–	﹤0.01%	833
2018 Q4	$10K	Hold	76	–	–	﹤0.01%	781
2018 Q3	$14K	Sell	76 -1,134	-94%	-$155K	﹤0.01%	747
2018 Q2	$162K	Sell	1,210 -890	-42%	-$83.9K	0.05%	298
2018 Q1	$156K	Buy	2,100 +1,100	+110%	+$73.3K	0.05%	291
2017 Q4	$55.6K	Hold	1,000	–	–	0.02%	471
2017 Q3	$45.4K	Hold	1,000	–	–	0.02%	492
2017 Q2	$33.7K	Sell	1,000 -300	-23%	-$9.77K	0.01%	646
2017 Q1	$38.5K	Sell	1,300 -700	-35%	-$21.7K	0.01%	593
2016 Q4	$54.9K	Sell	2,000 -1,400	-41%	-$56.2K	0.02%	518
2016 Q3	$209K	Buy	+3,400	New	+$103K	0.06%	296

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Winslow Evans & Crocker's SRPT Position: Q4 2020 in Review

Winslow Evans & Crocker held its Sarepta Therapeutics (SRPT) position steady in Q4 2020 at 75 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #900.

Winslow Evans & Crocker first reported a position in SRPT in Q3 2016 and has held it in 18 quarters since. The position peaked at $209K in Q3 2016. 454 funds tracked by Wall St. Rank hold SRPT as of Q4 2020.

Winslow Evans & Crocker held 75 shares of Sarepta Therapeutics worth $13K as of Q4 2020.
Winslow Evans & Crocker left its Sarepta Therapeutics share count unchanged in Q4 2020.
Sarepta Therapeutics made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #900 holding.
Winslow Evans & Crocker first reported a position in Sarepta Therapeutics in Q3 2016 and has held it in 18 quarters since.
Winslow Evans & Crocker's Sarepta Therapeutics position peaked at $209K in Q3 2016.
454 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.